Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Nebraska committee hears bipartisan bills to broaden statutory language for opioid reversal drugs
Summary
The Judiciary Committee heard a joint presentation on LB 5 and LB 195 to change Nebraska statute language from naming naloxone specifically to a broader term, "opioid overdose reversal medication," to allow newer FDA-approved drugs and generics to fall under standing orders and immunity protections.
Sen. Carolyn Bosn, chair of the Judiciary Committee, opened a combined hearing on LB 5 and LB 195, bills that would expand Nebraska statutory language to cover opioid overdose reversal medications beyond brand-name naloxone.
Supporters told the committee the change would let the state's standing order and civil/criminal immunity clauses cover generic naloxone products and future FDA-approved reversal agents, which could improve access in rural and underserved areas.
Sen. Glenn Meyer, sponsor of LB 195, said the bills would update state law to reflect market changes since the statute named naloxone specifically. “LB 195 will improve access to opioid overdose reversal medications by updating the…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
